Today was like earnings overload…let’s do a small re-cap:

Earnings Roundup

• Sanofi-Aventis has slashed 14 drugs in R&D, profit up 16%. [Bloomberg]

• Wyeth earnings were flat, but still beat Wall Street’s expectations, generic erosion does number on drugmaker. [WSJ]

• Human Genome Sciences reported a 1Q profit on delivery of anthrax treatment to national stockpile. [Yahoo!Finance]

• Hospira’s 1st-quarter profit doubled on a large tax benefit, lower operating expenses. [Yahoo!Finance]

• Geron, which received an OK from the FDA to conduct the first study of a human embryonic stem cell (hESC)-based therapy in man, lost $16.8M for Q1. [Yahoo!Finance]

• Finally, Viropharma had a Q1 loss of $59M, but had nearly $7M in net sales of Cinryze(TM), its C1 Esterase Inhibitor. [PR Newswire]

Other News, Money and Drugs

• Isis Pharmaceuticals and Alnylam Pharmaceuticals form new collaboration to develop single-stranded RNAi Technology, Alnylam will pay up to $31M. [BioSpace]

• Dendreon back up today by 100%, investors upset/happy, fortunes made/lost. [Bloomberg]

• Once the dust settles, Schering execs will have last laugh — all the way to the bank. [BNET Pharma]

• The first death from swine flu has occurred in Texas. Here’s the timeline. [Reuters UK]

• Finally, Vernalis to raise 24M GBP ($35M USD) to fund its development stage drug programs. [WSJ]

Image from msb

Related Posts